Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2014 08:00 ET | Source: Progenics Pharmaceuticals Inc.

Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

-Trial Data Show 1404 More Sensitive Than MRI in Detecting Primary and Metastatic Prostate Cancer- -Phase 1 and 2 Data Featured in Two Oral Presentations, Selected for Highlights...
October 06, 2014 16:31 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Receives $40 Million Milestone Following FDA Approval of RELISTOR for OIC Patients With Chronic Non-Cancer Pain

TARRYTOWN, N.Y., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today received a $40 million milestone payment from its worldwide collaboration partner, Salix...
September 22, 2014 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma

TARRYTOWN, N.Y., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today presented positive data from a pivotal phase 2 clinical study of Azedra™ in an oral...
August 08, 2014 08:00 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Second Quarter 2014 Financial Results

TARRYTOWN, N.Y., Aug. 8, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter and six months ended June 30. Net loss for...
July 31, 2014 16:00 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets Second Quarter Financial Results Call for August 8

TARRYTOWN, N.Y., July 31, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
July 14, 2014 07:05 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for Patients With Chronic Non-Cancer Pain

TARRYTOWN, N.Y., July 14, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark Baker will comment on the FDA's Relistor® Appeal Response in a...
June 12, 2014 15:40 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Schedules Investor Conference Call Following FDA Advisory Committee

TARRYTOWN, N.Y., June 12, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark Baker will comment on the FDA Advisory Committee meeting held this week,...
June 11, 2014 07:05 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Consider and Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists

TARRYTOWN, N.Y., June 11, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug...
June 02, 2014 14:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals CEO Mark Baker to Present at Jefferies Global Healthcare Conference

TARRYTOWN, N.Y., June 2, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating...
May 30, 2014 08:00 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals' PSMA ADC Data Selected for Poster Highlight Presentation at ASCO 2014

TARRYTOWN, N.Y., May 30, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company that is developing innovative approaches to targeting and treating prostate cancer,...